Cases have now reached 626 and could soon top the ignomious post-elimination record of 667, reached in 2014.
The US Centers for Disease Control and Prevention (CDC) recorded 78 more measles cases in the last week, a sign that ongoing outbreaks in several states are growing.
The 2019 total number of cases has jumped to 465 in 19 states, as Florida, Indiana, Massachusetts, and Nevada all reported their first cases of the year last week.
The US Centers for Disease Control and Prevention (CDC) today said measles counts have now grown to 268 cases in 15 states—62 more cases than the agency reported in a Mar 4 update. For comparison, the CDC reported 372 cases for all of 2018.
A 20th health zone in the Democratic Republic of the Congo (DRC) has confirmed its first Ebola case, according to today's update from the ministry of health. A young woman who was a case-contact of patient in Butembo, refused follow-up, and died is the first case-patient recorded in Lubero.
Scott Gottlieb, MD, announced today that he will resign as commissioner of the US Food and Drug Administration (FDA) in the coming weeks to spend more time with his family.
Today Saudi Arabia's ministry of health (MOH) reported a new MERS-CoV case in the city of Jeddah. The notice came in an epidemiologic week 3 notification.
Sanofi announced yesterday that the US Food and Drug Administration (FDA) has approved Vaxelis, a combination vaccine targeting six diseases.
Saudi Arabia's Ministry of Health (MOH) today reported one new MERS-CoV case for epidemiologic week 44. The MOH did not note any cases in epidemiologic week 43, which was last week.
The new case of MERS-CoV (Middle East respiratory syndrome coronavirus) occurred in a 74-year-old man from Riyadh who had contact with camels—a known risk factor for MERS transmission. The man is currently hospitalized.
The median vaccine exemption rate in kindergartners climbed for the third year in a row, to 2.2%, and 1.3% of 2-year-olds get no vaccines.
Cell culture–based inactivated influenza vaccine (ccIIV) was not significantly more effective than egg-based IIV (ebIIV) against influenza A during the 2017-18 flu season, according to new data presented at IDWeek that have not been peer reviewed.